@ARTICLE{
author={Syrigos Konstantinos,Abert Istvan,Andric Zoran G,Bondarenko Igor N,Dvorkin Mikhail,Galic Kristina,Galiulin Rinat,Kuchava Vladimer,Sriuranpong Virote,Trukhin Dmytro,Zhavrid Edvard,Fu Dongyue,Kassalow Laurent M,Jones Stephanie,Bashir Zahid},
year={2021},
title={Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)},
journal={BIODRUGS},
volume={35},
number={4},
pages={417-428},
document_type={Article},
} 

@ARTICLE{
author={Thongprasert Sumitra,Geater Sarayut L,Clement Dana,Abdelaziz Amr,Reyes-Igama Jasmin,Jovanovic Dragana D,Alexandru Aurelia,Schenker Michael,Sriuranpong Virote,Serwatowski Piotr,Suresh Sheethal,Cseh Agnieszka,Gaafar Rabab},
year={2019},
title={Afatinib in locally advanced/metastatic NSCLC harboring common <i>EGFR</i> mutations, after chemotherapy: a Phase IV study},
journal={LUNG CANCER MANAGEMENT},
volume={8},
number={3},
pages={-},
document_type={Article},
}